NHS National Framework for Romiplostim

NHS England

Value
£60,480,000
Published
10 Nov 2026
Deadline
Not stated
Procedure
Open procedure
Category
33600000 — Pharmaceutical products
Location
UKC, United Kingdom
Notice reference
106851-2026

Requirements summary

NHS England is planning a national framework agreement for romiplostim, a pharmaceutical product, under an open procedure with an estimated value of GBP 60,480,000 gross (GBP 50,400,000 net). The planned contract period runs from 1 January 2028 to 31 December 2028, with a renewal option extending to 31 December 2030. This is a pipeline notice, and suppliers planning to introduce the molecule or with questions are invited to contact the MPSC New Market Developments Team.

Key requirements

  • National framework agreement for romiplostim for NHS England
  • Estimated value GBP 60,480,000 gross (GBP 50,400,000 net)
  • Contract period 1 Jan 2028 to 31 Dec 2028, with renewal option to 31 Dec 2030
  • Delivery to seven English regions: North East, North West, Yorkshire and the Humber, East Midlands, West Midlands, East of England, South East and South West (London not listed)
  • Open procedure; suppliers may be SMEs
  • Pre-market engagement: suppliers planning to introduce the molecule should contact the MPSC New Market Developments Team by email
NHS National Framework for Romiplostim — NHS England | ProposAI